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Abstract
Objective To evaluate the health-related quality of life on a very long-term follow-up in patients treated with extracorporeal
membrane oxygenation (ECMO) during neonatal and pediatric age.
Design Prospective follow-up study.
Setting Pediatric Intensive Care Unit of a tertiary-care University-Hospital.
Patients Out of 20 neonates and 21 children treated with ECMO in our center, 24 patients underwent short-term neurological
follow-up. Twenty of them underwent long-term neurological follow-up.
Intervention Short-term follow-up was performed at 18months and consisted in clinical evaluation, electroencephalography, and
neuroimaging. Long-term follow-up was performed in 2017, at the mean period 19.72 years from ECMO (median 20.75, range
11.50–24.08) and consisted in a standardized questionnaires self-evaluation (PedsQL 4.0 Generic Core Scale) of health-related
quality of life and an interviewed about the presence of organ morbidity, school level, or work position.
Measurements and main results Sixty-one percent (25/41) of the patients survived within 30 days after ECMO treatment. Short-
term follow-up was performed in 24 patients (1 patient but died before the evaluation): 21 patients (87%) showed a normal
neurological status, and 3 developed severe disability. Long-term follow-up was performed in 20 long-term survivors (3 patients
were not possible to be contacted and considered lost to follow-up): mean age of patients at long-term follow-up was 21.23
(median 20.96, range 13.33–35.58) years; 90% (18/20) of them have no disability with a complete normal quality of life and 95%
have no cognitive impairment.
Conclusions ECMO represents a life-saving treatment for infants and children with respiratory and/or heart failure; survivors
show a good quality of life comparable to healthy peers.
Keywords Extracorporeal membrane oxygenation . Quality of life . Children .Mortality . Morbidity . Neurologic disorders
Introduction
Extracorporeal membrane oxygenation (ECMO) is a thera-
peutic strategy for patients of all ages affected by respiratory
and/or cardiac failure, refractory to conventional management,
whose mortality would have otherwise been high.
The first series of neonates were successfully treated with
ECMO for respiratory failure in the late 1970s [1, 2]. Over the
last 40 years, a significant increase in the use of ECMO was
reported by the Extracorporeal Life Support Organization
(ELSO) international registry, and progressively, the number
of centers performing ECMO increased [3]. It is estimated that
since now, 30,000 neonates due to respiratory failure and 6500
neonates due to cardiac failure have undergone ECMOworld-
wide; the same source data reported an overall survival of
approximately 75% and 40% for the two groups respectively.
In the pediatric population, the survival rate does not exceed
60% [4].
ECMO is associated with acute central nervous system
complications which increase both mortality and long-term
morbidity [5–8]. Acute neurologic lesions reported to ELSO
registry include clinical and electroencephalography (EEG)-
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registered seizures, hemorrhage, infarction, and brain death.
The development of these neurological sequelae may be relat-
ed to patients’ characteristics and clinical condition and to
complications developed before or during ECMO [9].
ELSO Register shows the incidence of acute neurological
complications according to three age categories (neonates,
children, adult). However, their long-term disability is not
reported. The neurological follow-up is limited to observa-
tional studies supported by single or multiple centers and the
period of evaluation usually lasted less than 5 years [10–13].
Despite all is known about the acute and long-term com-
plications of ECMO, little is known about the impact of these
events on the health-related quality of life (HRQoL) of survi-
vors. Actually, with the increasing success of ECMO and the
expanding population surviving this treatment, the HRQoL
has become a necessary end point of all studies on clinical
use of ECMO [14–19].
The aim of this study is to evaluate the HRQoL on a long-
term follow-up in patients treated with extracorporeal mem-
brane oxygenation (ECMO) during neonatal and pediatric age.
Materials and methods
The studied population is represented by all consecutive pa-
tients who received ECMO at the Pediatric Intensive Care
Unit of the University Hospital of Padua between 1993 and
2005 (Fig. 1) and underwent a comprehensive neurological
assessment 18 months after ECMO (short-term follow-up); a
HRQoL evaluation integrated by an interview about the pres-
ence of organ morbidity, school level, or work position was
administered more than 10 years after ECMO (long-term fol-
low-up).
In accordance with ELSO Registry’s criteria, patients 0–
30 days of age at treatment were codified as neonates, patients
older than 30 days but younger than 18 years as children.
Data from all ECMO patients, including demographic in-
formation, diagnosis, indication for ECMO, type of ECMO,
treatment course, and outcomes at the discharge have been
prospectively collected. There were no exclusion criteria.
Institutional review board (IRB) approved the study design
and patients and/or parents were informed and consent being
interviewed and using data for publication.
Short-term outcome
For the purpose of the study, all survivors received clinical and
instrumental neurodevelopmental assessments at 18 months
from ECMO, which was considered a short-term neurological
follow-up.
All patients received a clinical neurological assessment by
a pediatric neurologist.
EEG was obtained with the EB NeuroGalileo System,
using the 21-channels-EEG (the International 10/20 System).
Brainstem auditory evoked potentials, visual evoked poten-
tials, and somatosensory evoked potentials were performed
using a four-channel Multibasis system [20]. EEG and all
evoked potentials responses were interpreted by a pediatric
neurophysiologist.
For investigating neurological and cognitive development,
we used the Bayley Scale of Infant Development up to age of
30 months [21], the Stanford-Binet Intelligence test [22] be-
tween 30 months and 4 years, Wechsler Preschool and
Primary Scale of Intelligence [23] between 4 and 6 years,
and Wechsler Intelligence Scale for Children-Revised in pa-
tients older than 6 years [24]. A global score higher than 84
Fig. 1 Algorithm of studied
population
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was considered Bnormal,^ Bborderline^ between 70 and 84,
and Bdelayed^ less than 70. These scales were administered
by a psychologist.
Cerebral computed tomography or cerebral magnetic reso-
nance imaging was performed according to neurological
assessment.
Long-term outcome
The long-term follow-up was performed on May 2017 (11–
24 years after ECMO treatment) by contacting survivors by
phone. We administered a standardized questionnaire, the
PedsQL 4.0 [25], and we asked other open questions about
the presence of organ morbidity, school level, or work position.
The PedsQL 4.0 Generic Core Scale is a validated multidi-
mensional questionnaire, which explores HRQoL through 23-
items concerning 4 functional areas: Physical Functioning (8
items), Emotional Functioning (5 items), Social Functioning
(5 items), and School/Work Functioning (5 items).
The scoring system to evaluate and then to compare the
PedsQL 4.0 is as follows: items are reversed scored and line-
arly transformed to a 0–100 scale, if more than 50% of the
items in the scale are missing, the scale scores should not be
computed, the mean score is the sum of the items over the
number of items answered. HRQoL could be assessed by the
Total Scale Score (23 items) or by considering the Physical
Health Summary Score (8 items) or the combination of emo-
tional, social, and school dimensions in the Psychosocial
Health Summary Score (15 items).
The PedsQL 4.0 is age-adapted tool: for children between 2
and 18 years old, available in Child Self-Report form and in
Parent Proxy-Report form; for patient older than 18, the adult
form was used, (one version from 18 to 25 years of age and
one over the age of 25).
Considering the age of our long survivors (all > 13 years),
we used the PedsQL 4.0 age 13–18 and adult questionnaires.
All questions were answered by patients themselves, except
for one with a cognitive impairment, for whom the parent had
to answer it. We use the PedsQL 4.0 Italian-translated version.
In addition to the standardized and validated questions pro-
vided for in PedsQL 4.0, we formulated other questions in
order to investigate the organ morbidity (sensorineural, respi-
ratory, cardiac and gastrointestinal) and to further deepening
the psychiatric and psychological aspects, the neurological
and motor functionality, the level of education, and the prac-
ticed sport (Table 1).
Statistical analysis
Data were summarized with frequencies for categorical vari-
ables and mean, median, and range for continuous variables.
Descriptive tables were used to summarize data from the
short-term follow-up.
The analysis of long-term follow-up data was presented by
comparing the long-term survivors with published data for a
healthy sample and for a group of children with chronic health
conditions [26, 27], taking into account the age-related groups
of the patients. In the comparative analysis, the 35-year-old
patient was not considered due to her age. Obtained mean
scores were expressed in percentage with standard deviations
(SDs). For the comparison of data, the chi-square test was
used. We considered a statistically significant value of
p < 0.05.
Results
Between April 1993 and June 2005, of the 41 patients treated
with ECMO, 16 (39%) died during or within 30 days after
treatment. The survival rate was 65% in neonates (13 of 20),
Table 1 Non-standardized questionnaire submitted at the long-term
follow-up
Does he/she suffer from any diseases? Specify.
Does he/she take any drugs?
Does he/she going to school/university?
Has he/she repeated school years?
Has he/she had a special education teacher?
Does he/she any sport activity? Which? How often?
Does he/she suffer from neurological disorders (epilepsy, other)?
Is he/she indipendent in daily activities?
Does he/she have moving impariment / walking difficulty?
Does he/she suffer from sleeping disorders?
Does he/she suffer from anxiety / psychological disorders / psychosis /
aggressive episodes?
Does he/she take any psychotropic medication?
Does he/she underwent neuroimaging? Which / Date / outcome
Does he/she underwent EEG/neurophysyology tests? Date / outcome
Does he/she present eye disorders?
Does he/she present hearing disorders?
Has he/she been suffering respiratory disorders over the years? When?
How often?
Does he/she underwent spirometry? Data / outcome
Does he/she take any medications for respiratory disorders?
Has he/she any cardiac disease?
Does he/she take any medications for cardiac disorders?
Does he/she underwent ECG/echocardiography? Data / outcome
Has he/she had any injuries associated with vascular incannulation?
Does he/she underwent Colordoppler US? Data / outcome
Has he/she had any growth deficit?
Has he/she any gastroenterologic disorders?
Does he/she take any medications for gastroenterologic disorders?
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57% (12 of 21) in pediatric patients. Among all survivors
(61%, 25/41), 12 (57%) were male.
In the neonatal population, indications for ECMO were
inhalation of meconium (n = 6), persistent pulmonary hyper-
tension of the newborn (PPHN) (n = 3), air leak syndrome
(n = 2), left diaphragmatic hernia (n = 1), and sepsis (n = 1).
In the pediatric population, indications were pneumonia (n =
4), air leak syndrome (n = 3), ARDS (n = 2), heart failure sec-
ondary to myocarditis (n = 1), asthma (n = 1), and congenital
pulmonary fistulas (n = 1). No ECMO support was started
during cardiopulmonary resuscitation.
The mean duration of treatment per patient was globally
199 h (range 53–688 h), 112 h (range 53–240) in neonates,
294 h (range 11–688) in children. Venous-arterial (VA)
ECMO was performed in 7 patients, veno-venous (VV)
ECMO in 18 patients (in 3 of them it was converted to VA
ECMO).
Short-term follow-up
Of the 25 survivors, 24 underwent a short-term neurological
follow-up; one pediatric patient died before the assessment.
Tables 2 and 3 reported, for each patient, clinical and in-
strumental neurodevelopment assessment and the correspond-
ing results.
Long-term follow-up
In 2017, of the 24 patients evaluated at 18-month follow-up,
20 (49%) survivors were interviewed by the submission of
PedsQL 4.0 questionnaire. One child had died 3 years after
ECMO treatment for a respiratory failure, 3 patients were not
possible to be contacted so we considered them lost to follow-
up.
For the 20 patients considered in this long-term follow-up
cohort, the mean age at follow-up was 21.23 (median 20.96,
range 13.33–35.58) years, and the mean period from ECMO
was 19.72 years (median 20.75, range 11.50–24.08). Two out
of the three patients with neurologic impairment have been
interviewed.
All the questionnaires have been considered valid because
the not-answered questions were minimal. Table 4 reports our
patients’ PedsQL 4.0 Scores.
The non-standardized questionnaire reported 1 patient af-
fected by spastic quadriplegia with vision impairment and
seizure controlled by therapy, 1 patient affected by
hemiparesis with drug-resistant epilepsy without cognitive
disability, and 18 patients without any neurological impair-
ment. Excluding the patient with spastic quadriplegia who
has a global dependence in daily activities, 19 patients are
100% self-sufficient. They have regularly completed the
school without missing years or receiving any supplementary
support; at the moment, 2 children are at middle school, 2 are
at high school, 5 have been graduated, 1 was graduated at
short course university (3 years), 7 are attending university,
and 2 are working. Five patients do regularly sport activity
(one tennis coach, one basketball coach). The patient affected
by hemiparesis has the driving license. One patient suffers
from sleep disorder; none has anxiety disorder. None refers
respiratory, cardiac, gastroenterological, or growth deficit.
Discussion
This paper reports the experience of a group of patients un-
dergoing ECMO over a period of 12 years, with an overall
survival rate of 61% at 30 days. This rate of survival is higher
than what has been reported in previous series [5, 11, 13–15,
28–30] and comparable with ELSO registry data [4]. In a
recent study, it was reported that patients undergoing ECMO
after cardiac surgery showed a higher mortality especially if
extracorporeal support lasted more than 4 days (mean time)
[31]. In our study, the characteristics of our sample (96% of
patients had a non-cardiac indication for ECMO support) may
explain a high survival rate despite a long mean time on
ECMO (8.2 days).
In this study, we described neurological morbidity and
HRQoL assessment by a very long period of time from
ECMO, between 11 and 24 years; to our knowledge, this is
the longest one compared with previously reported study
[14–16, 28, 32]. Almost all long-term survivors of ECMO in
our sample have no disability (18/20), and 95% of evaluated
patients have no cognitive impairment. Considering all our
ECMO population, the 43.9% of them (18/41) has a complete
normal quality of life: a very encouraging rate when we ana-
lyze that these patients would had have an 80 to 100% mor-
tality without ECMO treatment.
Moreover, in our report, most of neonates with acute cen-
tral nervous system’s injuries showed by neuroimaging had
not neurological deficit at 18-month follow-up, and later. This
is probably due to the capability of the neuronal pattern to
compensate and change itself after a damage, developing
new connections especially in the firsts periods of life. Most
studies, however, performed a neurological follow-up in neo-
nates limited to a period of observation up to 5 years after
ECMO and reported a risk of cognitive delay or behavioral
problems that could contribute to school failure [33–36].
The HRQoL of the children who underwent ECMO we
studied is similar to the ones reported in healthy population
and in patients affected by chronic conditions (Tables 5 and 6).
This is in contrast with what is reported by other authors
which indicates a lower HRQoL in children surviving
ECMO treatment in comparison with the non-treated popula-
tion [14–17].
The different instruments used to test the HRQoL, the dif-
ferent Bsize^ of the study populations considered, and the
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different follow-up periods considered might explain the dif-
ferent results.
Castello et al. [14] compared the HRQoL of a popula-
tion of children, aged 5 and 18 years who underwent
ECMO for cardiac conditions with the ones documented
in a cohort of healthy children and with a group of young
patients affected by cardiac conditions but not treated with
ECMO. They used the CHQ-PF87 in 17 patients and the
Child Health Questionnaire Parent Form (CHQ-PF-50), in
41 patients’ parents. Looking at the psychosocial func-
tioning, the ECMO group obtained similar results to both
comparator groups, but a significant better physical
Table 2 Short-term neonates’ follow-up
Patient
no.
Diagnosis Age by
ECMO
(days)
Neuroimaging
during ECMO
18-month
neuroimaging
18-month
neurologic
evaluation
18-month
EEG
18-month PEV 18-
month
BAERS
18-month SEP
1 CDH 1 NP N N N N N N
2 Air leak
sdr.
16 P
Mild edema. Mild
talamic
hyperecogenicity
N N N N N N
3 Sepsis 1 P
Posterior
hemispheric
hypodensities. 2°
hemorrhage
P
Atrophy and
bilateral
hypodensi-
ty
P
Evolution in
tetraparesis.
Pathologic
Bayley
score
P
asymmetry
and
temporal
anoma-
lies
P
Pathological,
retino-cortical
transmission
N P
Suffering of the
left
somatosenso-
rial ascending
way
4 MAS 2 P
Subarachnoid
hemorrhage
N N N N N P
Cortical
suffering
(> left)
5 PPHN 2 P
Left choroid plexus
hemorrhage
N N N N N N
6 ALS 2 P
Right frontal
ischemia.
White matter frontal
and occipital
hypodensities
N N N N N N
7 PPHN 1 P
Ischemic lesion with
left posterior
temporal
hemorrhagic
infarction left
N N N N N N
8 MAS 5 N N N N N N N
9 MAS 1 P
Mild left
periventricular
hyperechogenicit-
y
N N NE N N N
10 PPHN 3 N NE N N N N N
11 MAS 0 N NE N N P
Mild occipital
alterations of
retino-cortical
transmission and
cortical activation
N N
12 MAS 1 N NE N N N N N
13 MAS 0 N N N N NE NE N
ALS, air leak syndrome; CHD, congenital diaphragmatic hernia; MAS, meconium aspiration syndrome; N, normal; NP, not performed; P, pathologic;
PPHN, persistent newborn pulmonary hypertension
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summary score was reported in healthy children’s respect
on patients affected by cardiac diseases and ECMO-
treated group. Moreover, parents of patients previously
treated with ECMO also reported, in non-negligible per-
centage, problems such as deficit of attention, speech or
auditory disorder, and developmental or mental
retardation.
Costello et al. [14] also underlined the relationship between
acute neurologic events, occurred during ECMO, and the im-
pact on the quality of life later in time.
Garcia Guerra et al. [16] analyzed the HRQoL of 47 cardiac
patients aged up to 5 years, at about 4 years from ECMO
treatment, by applying the PedsQL 4.0 Generic Core Scales.
The results obtained were comparedwith those documented in
Table 4 Long-term follow-up:
patients’ PedsQL 4.0 scores Patient no. PedsQL 4.0 Scores
Total Physical Psychosocial Emotional Social School/
Work
1 Adult 18–25 79.35 100 68.30 55.00 85.00 65.00
2 Adult 18–25 85.87 100 78.33 60.00 100.00 75.00
3 Adult 18-25a 13.75 6.25 20.28 33.33 12.50 15.00
4 Adult 18–25 81.52 90.62 76.67 70.00 90.00 70.00
5 Adult 18–25 86.96 93.75 83.33 70.00 95.00 85.00
6 Adult 18–25 85.87 100 78.33 65.00 90.00 80.00
7 Adult 18–25 76.09 96.87 65.00 40.00 85.00 70.00
8 Adult 18–25 80.43 90.62 75.00 65.00 90.00 70.00
9 Adult 18–25 71.74 84.37 65.00 80.00 55.00 60.00
12 Adolescent
13–18
82.61 93.75 76.67 70.00 80.00 80.00
13 Adolescent
13–18
80.43 84.37 78.33 80.00 80.00 75.00
14 Adult 18–25 59.78 100 78.33 60.00 100.00 75.00
15 Adult 18–25 78.26 75 80.00 85.00 75.00 80.00
17 Adult > 25 91.30 96.87 88.33 80.00 85.00 100.00
18 Adult 18–25 90.22 93.75 88.33 75.00 100.00 90.00
19 Adult 18–25 86.96 96.87 81.67 70.00 95.00 80.00
20 Adult 18–25 83.69 93.75 78.33 65.00 100.00 70.00
21 Adult 18–25 84.78 100 76.67 65.00 100.00 65.00
22 Adolescent
13–18
76.09 65.62 81.67 80.00 80.00 85.00
23 Adolescent
13–18
85.87 96.87 80.00 85.00 80.00 75.00
a Parent Proxy Form
Table 5 PedsQL 4.0 Scale
scores: comparison between
ECMO survivors, healthy
population, and chronic ill
patients (age between 13 and
18 years old)
ECMO group
(n = 4)
Healthy group
(n = 5079)*
p (ECMO vs
HEALTHY)
Chronic group
(n = 574)*
p (ECMO vs
CHRONIC)
Scores % SD % SD % SD
Total 81.25 3.55 83.91 12.47 0.88 74.16 15.38 0.75
Physical 85.15 12.17 87.77 13.12 0.87 79.47 17.07 0.78
Psychosocial 79.16 1.86 81.83 13.97 0.89 71.32 17.13 0.73
Emotional 78.75 5.44 79.21 18.02 0.98 69.32 21.36 0.68
Social 80.00 0.00 84.97 16.71 0.78 76.36 21.57 0.86
School 78.75 4.14 81.31 16.09 0.89 68.27 19.09 0.65
*Varni JW et al. BThe PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity^
Ambul Pediatr. 2003: 329–41
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a cohort of healthy population, in a group of children with
chronic disease and in one composed by pediatric patients
with congenital heart disease undergoing cardiopulmonary
bypass in infancy. They concluded that parents of children
undergoing ECMO reported a lower score of HRQoL if com-
pared to the other groups.
Wagner et al. [30] submitted a cohort of 22 children treated
with ECMO for cardiac and respiratory failure 7 years after
the ECMO treatment to a clinical neurological and neuropsy-
chological assessments, neuroimaging and electrophysiology
studies, and HRQoL evaluation. The authors reported a cog-
nitive impairment in 68% of their study population and a
parents-reported reduction in quality of life in 36%; 62% of
patients had received a supplementary support in kindergarten
or school.
Hamrick et al. [32] on follow-up a mental delay in 29% of
ECMO survivors, Lequier et al. [33] in 50% of them.
Compared to data published byWagner, our long-term sur-
vivor population had a cognitive deficit of 5% (1/20).
Fleck evaluated the HRQoL by submitting the KINDL
questionnaire to 19 patients between 7 months and 30 years
old [15] at about 5 years from ECMO. He concluded that the
parents’ reports of quality of life are lower than those from a
healthy population, but in the age group of 12 and above, the
self-assessed HRQoL is similar to that of the healthy popula-
tion. Also, our data confirmed this issue, because all patients
were over 13 years old and 19/20 answered the questions on
their own, therefore providing a personal opinion on their
quality of life that was similar to the report provided by
healthy peers. We infer that the perception of being a survivor
is acquired with the maturity of the person itself and overs the
years; it might influence the evaluation of their quality of life.
Limitations of this report firstly include the small number
of patients. Secondly, the neurological (clinical and instru-
mental) evaluation was not complete for all patients at the
short-term follow-up and it was not repeated at the time of
long-term follow-up. In our long-term evaluation, validated
tests to assess motor and cognitive achievements were not
included. Our self-made questionnaire, as it is not standard-
ized, is not comparable with other surveys, it is not also
reapplied because not validated, however it investigates as-
pects of the daily life of these patients which are not dealt in
the validated questionnaires.
Conclusions
Our data suggest that survivors from non-cardiac indication
ECMOmay show a quality of life similar to peers. Due to the
increasing number of centers performing this treatment, there
is a great interest towards the evaluation of the quality of life in
survived pediatric patients; however, a globally recognized
instrument to assess their quality of life still not exists.
The necessity of drawing up guidelines for the proper ex-
ecution of the neurological follow-up, in terms of which
exams should be done and when they should be done, and
the necessity of determine an useful and globally recognize
tool for the quality of life’s assessment in these patients must
once again be reiterated in order to allow that data, from dif-
ferent centers, would be collecting, comparing, and using for
further studies.
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